Key facts
- Kanvas’s last known valuation is $50.0M.
- It has raised $24.5M; the latest was Seed Round ($12.5M) in Jul 2024.
- Notable investors include Mana Ventures, DCVC, FemHealth Ventures, Ki Tua Fund, Germin8 Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Kanvas
- ·The full record, as it builds
Funding rounds
No funding rounds for Kanvas are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kanvas
Developer of a healthcare imaging technology designed to bring microbiome drug discovery into focus and microbial detection. The company develops a multiplexed imaging technology for microbial detection by illuminating microbial life with the help of cells, providing researchers with tools for research, and creating cures for infectious diseases.
- Sector
- Healthcare
- HQ
- Monmouth Junction, NJ, United States
- Founded
- 2020
- Employees
- 34
- Website
- kanvasbio.com/
- Ownership
- Privately Held (backing)
Kanvas doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kanvas shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kanvas in its N-PORT filings yet. We sweep new filings monthly.